Literature DB >> 22032882

Malignant otitis externa: an Australian case series.

Ronald Chin1, Phoebe Roche, Elizabeth Sigston, Neil Valance.   

Abstract

OBJECTIVES: To establish a clinicopathological profile of malignant otitis externa (MOE) in an Australian tertiary referral institution. STUDY
DESIGN: Retrospective cohort outcomes study.
METHODS: 24 patients were identified with MOE between January 1998 and July 2007. Patients were classified into Radiological Grades I-IV. Laboratory investigations Including C-reactive protein (CRP), white cell count (WCC), glycosylated haemoglobin (HBA1c) and average glucose level over admission were recorded.
RESULTS: Radiological Grade was significantly associated with duration of therapy (rank correlation 0.57, p = 0.004). CRP was a useful indicator confirming disease resolution. Diabetics with MOE had elevated average blood sugar levels during their Hospital admission (p < 0.001) and had poor overall glycaemic control represented by Elevated HBA1c scores (p < 0.001).
CONCLUSIONS: Malignant otitis externa is a rare disease, which is best managed in a multidisciplinary team setting. This practical grading system can be used to predict the duration of therapy at time of diagnosis, which enables the efficient utilisation of Hospital resources. Poorly controlled diabetics are more susceptible to developing. MOE than diabetics with satisfactory glycaemic control and may represent a subgroup of more brittle diabetics. CRP combined with appropriate clinical and radiological investigations is useful in assessing disease resolution.
Copyright © 2011 Royal College of Surgeons of Edinburgh (Scottish charity number SC005317) and Royal College of Surgeons in Ireland. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22032882     DOI: 10.1016/j.surge.2011.09.004

Source DB:  PubMed          Journal:  Surgeon        ISSN: 1479-666X            Impact factor:   2.392


  1 in total

1.  Predictive factors in treatment response of malignant external otitis.

Authors:  Alireza Zonnour; Abolfazl Jamshidi; Sasan Dabiri; Mehrdad Hasibi; Ardavan Tajdini; Narges Karrabi; Nasrin Yazdani
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-06-25       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.